Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06350981
PHASE2/PHASE3

Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion

Sponsor: Foundation for Orthopaedic Research and Education

View on ClinicalTrials.gov

Summary

The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 0.25% Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% Bupivacaine HCl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores.

Official title: Analgesic Requirement for Post-Operative Pain Control in Elective 1-3 Level Transforaminal Lumbar Interbody Fusion: Comparison of Thoracolumbar Interfascial Plane Block With Exparel to Bupivacaine HCl

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2024-04-30

Completion Date

2026-03-01

Last Updated

2025-02-25

Healthy Volunteers

No

Interventions

DRUG

Exparel

20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine

DRUG

Bupivacain

Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL

Locations (1)

Foundation for Orthopaedic Research and Education

Tampa, Florida, United States